Journal ArticleDOI
Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis.
TLDR
Examination of the effects of chemopreventive agents on the surface expression of programmed death-1-ligand 1, a negative regulator of T cell anti-tumor immunity, reveals a potential link between chemotherapy and cancer immunoresistance.About:
This article is published in Molecular Immunology.The article was published on 2008-03-01. It has received 242 citations till now. The article focuses on the topics: T cell & Cancer.read more
Citations
More filters
Journal ArticleDOI
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott J. Antonia,A. Villegas,Davey B. Daniel,David Vicente,Shuji Murakami,Rina Hui,Takashi Yokoi,Alberto Chiappori,Ki Hyeong Lee,Maike de Wit,Byoung Chul Cho,M. Bourhaba,Xavier Quantin,Takaaki Tokito,Tarek Mekhail,David Planchard,Young-Chul Kim,Christos S. Karapetis,Sandrine Hiret,Gyula Ostoros,Kaoru Kubota,Jhanelle E. Gray,Luis Paz-Ares,Javier de Castro Carpeño,Catherine Wadsworth,Giovanni Melillo,Haiyi Jiang,Y. Huang,Phillip A. Dennis,Mustafa Ozguroglu,Pacific Investigators +30 more
TL;DR: Progression‐free survival was significantly longer with durvalumab than with placebo, and safety was similar between the groups, and the secondary end points also favored durvalsumab.
Journal ArticleDOI
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco,Victor H. Salinas,Keturah E. Brown,Vijay K. Vanguri,Vijay K. Vanguri,Gordon J. Freeman,Vijay K. Kuchroo,Arlene H. Sharpe,Arlene H. Sharpe +8 more
TL;DR: PD-L1 can inhibit T cell responses by promoting both the induction and maintenance of iT reg cells, defining a novel mechanism for iT reg cell development and function, as well as a new strategy for controlling T reg cell plasticity.
Journal ArticleDOI
Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer.
TL;DR: Immune Check Point inhibitors have demonstrated efficacy in advanced stage solid tumors including non-small cell lung cancer (NSCLC), CTLA4, programmed cell death-1 (PD-1) and PD-1 ligand 1 ( PD-L1) inhibitors being the most studied drugs.
Journal ArticleDOI
In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy.
Chao Wang,Jinqiang Wang,Xudong Zhang,Shuangjiang Yu,Di Wen,Quanyin Hu,Yanqi Ye,Hunter N. Bomba,Xiuli Hu,Zhuang Liu,Gianpietro Dotti,Zhen Gu +11 more
TL;DR: A ROS-responsive hydrogel scaffold controls release of gemcitabine and immune checkpoint inhibitor for enhanced antitumor activity and promotes an immune-mediated tumor regression in the tumor-bearing mice, with prevention of tumor recurrence after primary resection.
Journal ArticleDOI
PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients
Feng Shi,Ming Shi,Zhen Zeng,Rui-Zhao Qi,Zhenwen Liu,Ji-Yuan Zhang,Yongping Yang,Po Tien,Fu-Sheng Wang +8 more
TL;DR: Characterizing circulating and intratumor PD‐1/PD‐L1 expression and analyzing their association with disease progression in a cohort of hepatitis B virus‐infected patients provides evidence for a new therapeutic target in HCC patients.
References
More filters
Journal ArticleDOI
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
Gordon J. Freeman,Andrew J. Long,Yoshiko Iwai,Karen Bourque,Tatyana Chernova,Hiroyuki Nishimura,Lori Fitz,Nelly Malenkovich,Taku Okazaki,Michael C. Byrne,Heidi F. Horton,Lynette A. Fouser,Laura L. Carter,Vincent Ling,Michael R Bowman,Beatriz M. Carreno,Mary Collins,Clive Wood,Tasuku Honjo +18 more
TL;DR: It is reported here that the ligand of PD-1 (PD-L1), an immunoinhibitory receptor expressed by activated T cells, B cells, and myeloid cells, is a member of the B7 gene family.
Journal ArticleDOI
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion
Haidong Dong,Scott E. Strome,Diva R. Salomao,Hideto Tamura,Fumiya Hirano,Dallas B. Flies,Patrick C. Roche,Jun Lu,Gefeng Zhu,Koji Tamada,Vanda A. Lennon,Esteban Celis,Lieping Chen +12 more
TL;DR: It is reported here that, except for cells of the macrophage lineage, normal human tissues do not express B7-H1 and the findings have implications for the design of T cell–based cancer immunotherapy.
Journal ArticleDOI
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
TL;DR: The results suggest that the expression of PD-L1 can serve as a potent mechanism for potentially immunogenic tumors to escape from host immune responses and that blockade of interaction between PD-1 andPD-L may provide a promising strategy for specific tumor immunotherapy.
Journal ArticleDOI
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
TL;DR: It is shown that binding of MIC induces endocytosis and degradation of NKG2D, a mode of T-cell silencing that may promote tumour immune evasion and, by inference, compromise host resistance to infections.
Journal ArticleDOI
Interferons, immunity and cancer immunoediting.
TL;DR: The roles of the IFNs are discussed, not only in cancer immunosurveillance but also in the broader process of cancer immunoediting.
Related Papers (5)
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian,F. Stephen Hodi,Julie R. Brahmer,Scott N. Gettinger,David Smith,David F. McDermott,John D. Powderly,Richard D. Carvajal,Jeffrey A. Sosman,Michael B. Atkins,Philip D. Leming,David R. Spigel,Scott J. Antonia,Leora Horn,Charles G. Drake,Drew M. Pardoll,Lieping Chen,William H. Sharfman,Robert A. Anders,Janis M. Taube,Tracee L. McMiller,Haiying Xu,Alan J. Korman,Maria Jure-Kunkel,Shruti Agrawal,Dan McDonald,Georgia Kollia,Ashok Kumar Gupta,Jon M. Wigginton,Mario Sznol +29 more
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer,Scott S. Tykodi,Scott S. Tykodi,Laura Q.M. Chow,Wen-Jen Hwu,Suzanne L. Topalian,Patrick Hwu,Charles G. Drake,Luis H. Camacho,John S. Kauh,Kunle Odunsi,Henry C. Pitot,Omid Hamid,Shailender Bhatia,Renato G. Martins,Keith D. Eaton,Shuming Chen,Theresa M. Salay,Suresh Alaparthy,Joseph F. Grosso,Alan J. Korman,Susan M. Parker,Shruti Agrawal,Stacie M. Goldberg,Drew M. Pardoll,Ashok Kumar Gupta,Jon M. Wigginton +26 more
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
Julie R. Brahmer,Karen L. Reckamp,Paul Baas,Lucio Crinò,Wilfried Eberhardt,Elena Poddubskaya,Scott J. Antonia,Adam Pluzanski,Everett E. Vokes,Esther Holgado,David M. Waterhouse,Neal Ready,Justin F. Gainor,Osvaldo Arén Frontera,Libor Havel,Martin Steins,Marina Chiara Garassino,Joachim G.J.V. Aerts,Manuel Domine,Luis Paz-Ares,Martin Reck,Christine Baudelet,Christopher T. Harbison,Brian Lestini,David R. Spigel +24 more